Challenging Dynamics in Immuno-oncology: Access, Reimbursement, and Provider Perspectives

About Promidian

Promidian is a management consulting firm that is focused on the pharmaceutical, biotechnology, and life sciences industries. We combine deep industry and functional area knowledge with specialized expertise in market assessment, analytics, and strategy development to assist life sciences executives in addressing their most pressing business challenges. In providing our services, we collaborate with clients to increase value across the product lifecycle by helping them to understand and address the strategic, tactical, and operational implications of the rapidly evolving - and increasingly complex - market dynamics facing pharmaceutical and biotech companies today.

Challenging Dynamics in Immuno-oncology: Access, Reimbursement, and Provider Perspectives

The recent launches of Kymriah (Novartis) and Yescarta (Kite/Gilead) mark a new generation of premium-priced, yet effective, immuno-oncology agents. In the near term, these and similar products likely will be reimbursed. However, market dynamics almost certainly will change over time. As additional companies follow suit and the market becomes more crowded, immuno-oncology products are likely to face increasing scrutiny and headwinds from an access and reimbursement standpoint. Companies marketing immuno-oncology agents must be prepared to thrive in a more challenging environment that could include restricted access, preferred coverage guidelines, and other payer cost-control measures. In addition, companies must be increasingly conscious of the patient and provider perspectives related to reimbursement, patient management, the patient experience, caregiver support, and other issues that are changing as a result of advances in immuno-oncology. Bringing together three panelists with differing perspectives for a holistic view, this webinar will outline key immuno-oncology trends and implications that biopharmaceutical decision makers need to consider. Panelists will include a decision maker from a leading payer organization, an oncology opinion leader, and a strategic consultant from Promidian. The following topics will be discussed:

Watch Webinar Archive

Panelists:


Jeff Liepman
Jeff Liepman
Executive Vice President
Promidian
xxxx xxxx, MD*
xxxx xxxx, MD*
Medical Director
Large Health Insurance Company
Michael Bishop, MD
Michael Bishop, MD
Professor of Medicine
Director, Hematopoietic Stem Cell Transplantation Program
The University of Chicago Medicine

Moderated By:


Don Sharpe
Don Sharpe
President
OBR
*Panel member wishes to remain anonymous